ArticlePalliative medicine reports
Palliative Management of Malignant Esophago-Tracheobronchial Fistula Using Covered Self-Expandable Metallic Stents: A Single-Center Case Series.
Article in Palliative medicine reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant esophago-tracheobronchial fistula (ETBF) is a devastating complication of thoracic malignancies, especially advanced esophageal cancer. Covered self-expandable metallic stents (CSMSs) have emerged as a minimally invasive palliative option. Methods: Between May 2015 and June 2021, seven patients with malignant ETBF (five men and two women; mean age 63 ± 5.8 years) underwent CSMS placement at our institution. Primary diseases included five esophageal cancers and two metastatic mediastinal carcinomas. Clinical characteristics, technical success, complications, and outcomes were retrospectively reviewed. Results: No intraoperative mortality occurred. All patients experienced improvement in dysphagia and/or airway aspiration, allowing resumption of oral intake, which was maintained for a median of 62 days (range, 10-124 days). Median post-stenting survival was 104 days (range, 14-250 days). Conclusion: CSMS placement is a safe and effective palliative treatment for malignant ETBF, preventing aspiration pneumonia and restoring oral intake, thereby supporting home-based care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.